This article is more than 5 years old. Information may no longer be current.
VIDEO: Chey discusses benefits of tenapanor in IBS-C
Click Here to Manage Email Alerts
LAS VEGAS — In this exclusive video from ACG 2016, William D. Chey, MD, professor of medicine, director of the GI Physiology Lab, and co-director of the Michigan Bowel Control Program at the University of Michigan, Ann Arbor, discusses the results of a phase 2b randomized controlled trial of tenapanor (Ardelyx), a small molecule that inhibits sodium reabsorption via the NHE3 receptor, in patients with constipation predominant irritable bowel syndrome.
While it was previously reported that 50 mg tenapanor twice daily led to an increased rate of complete spontaneous bowel movements per week and improved abdominal pain scores, “we actually presented data on a variety of clinically relevant endpoints like adequate relief, constipation severity, IBS severity and treatment satisfaction,” Chey said. “We’re very pleased to report that tenapanor at that higher dose led to statistically significant improvements in those very patient-focused clinical outcomes.”
Reference:
Chey WD, et al. Abstract #64. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 17-19, 2016; Las Vegas, NV.
Disclosures: Chey reports he serves as a consultant for Albreio, Allergan, Ardelyx, IM Health, Ironwood, Nestle, Prometheus, QOL Medical, Salix, Syn Biologic and Takeda, and has received grant/research support from Ironwood, Nestle, Perrigo and Prometheus.
Collapse
Read more about
Click Here to Manage Email Alerts